We are live on
!
Find out more
Aviva Portfolio holdings
AUM
$59.6B
1-Year Est. Return
28.44%
This Fund
S&P 500
This Quarter
Est. Return
+5.72%
1 Year Est. Return
+28.44%
3 Year Est. Return
+95.57%
5 Year Est. Return
+123.24%
10 Year Est. Return
+442.53%
AUM
$20.5B
AUM Growth
+$1.25B
(+6.5%)
Cap. Flow
+$361M
Cap. Flow
% of AUM
1.76%
Top 10 Holdings %
Top 10 Hldgs %
22.52%
Holding
1,000
New
89
Increased
345
Reduced
485
Closed
62
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ferguson
FERG
|
+$309M |
| 2 |
Stellantis
STLA
|
+$198M |
| 3 |
Mastercard
MA
|
+$54.7M |
| 4 |
Truist Financial
TFC
|
+$47.4M |
| 5 |
Walt Disney
DIS
|
+$41.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$55.7M |
| 2 |
Skyworks Solutions
SWKS
|
+$47.7M |
| 3 |
RTX Corp
RTX
|
+$38.8M |
| 4 |
Adobe
ADBE
|
+$35.9M |
| 5 |
Intercontinental Exchange
ICE
|
+$32.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.63% |
| 2 | Financials | 14.68% |
| 3 | Consumer Discretionary | 13.35% |
| 4 | Healthcare | 12.77% |
| 5 | Communication Services | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Dr. Reddy's Laboratories
RDY
$9.8B
| $275K | ﹤0.01% |
22,365
+3,065
| +16% | +$39.4K |
|
927
Lennar Class B
LEN.B
$19.9B
| $256K | ﹤0.01% |
+3,269
| New | +$218K |
|
928
YPF
YPF
$19.7B
| $243K | ﹤0.01% |
59,100
| – | – |
|
929
CNA Financial
CNA
$14.9B
| $241K | ﹤0.01% |
5,404
-280
| -5% | -$11.9K |
|
930
Blackstone
BX
$104B
| $213K | ﹤0.01% |
+2,860
| New | +$197K |
|
931
Pan American Silver
PAAS
$17.9B
| $205K | ﹤0.01% |
6,859
-60
| -0.9% | -$1.95K |
|
932
Telecom Argentina
TEO
$5.84B
| $162K | ﹤0.01% |
29,300
| – | – |
|
|
AUY
933
DELISTED
Yamana Gold, Inc.
AUY
| $159K | ﹤0.01% |
36,699
+1,670
| +5% | +$7.97K |
|
934
United Microelectronic
UMC
$42.9B
| $140K | ﹤0.01% |
15,407
| – | – |
|
935
Itaú Unibanco
ITUB
$89.8B
| $103K | ﹤0.01% |
28,407
| – | – |
|
936
Cemex
CX
$16.9B
| $88K | ﹤0.01% |
12,601
| – | – |
|
937
Banco Bradesco
BBD
$37.4B
| $69K | ﹤0.01% |
17,769
| – | – |
|
938
B2Gold
BTG
$4.98B
| $46K | ﹤0.01% |
10,615
| – | – |
|
939
Acadia Pharmaceuticals
ACAD
$4.51B
| – | – |
-30,740
| Closed | -$1.64M |
|
940
Agios Pharmaceuticals
AGIO
$2.08B
| – | – |
-34,412
| Closed | -$1.49M |
|
941
Allogene Therapeutics
ALLO
$625M
| – | – |
-35,003
| Closed | -$883K |
|
942
Ambarella
AMBA
$3.04B
| – | – |
-24,904
| Closed | -$2.29M |
|
943
Anterix
ATEX
$1.72B
| – | – |
-34,649
| Closed | -$1.3M |
|
|
BAND
944
Bandwidth Inc
BAND
$1.18B
| – | – |
-7,444
| Closed | -$1.14M |
|
945
Brown-Forman Class A
BF.A
$13.7B
| – | – |
-18,381
| Closed | -$1.35M |
|
946
BlackLine
BL
$1.9B
| – | – |
-14,462
| Closed | -$1.93M |
|
947
BellRing Brands
BRBR
$1.55B
| – | – |
-65,803
| Closed | -$1.6M |
|
948
Codexis
CDXS
$158M
| – | – |
-105,216
| Closed | -$2.3M |
|
949
Chegg
CHGG
$116M
| – | – |
-18,390
| Closed | -$1.66M |
|
950
Corcept Therapeutics
CORT
$9.98B
| – | – |
-70,676
| Closed | -$1.85M |
|
Similar funds
QCM
NAMI
Aviva's Q1 2021 Portfolio in Review
As of Q1 2021, Aviva held 1,000 positions worth $20.5B, up 6.5% from $19.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Aviva's Q1 2021 filing shows 89 new, 345 increased, 485 reduced and 62 closed positions. Its largest new stake was Ferguson: 2,534,285 shares worth $302M. The largest sale was Apple, an estimated $55.7M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
- Aviva's largest Q1 2021 buy was Ferguson: 2,534,285 shares worth $302M.
- Aviva added most to Stellantis in Q1 2021, an estimated $198M increase.
- Aviva's biggest Q1 2021 reduction was Apple, cutting an estimated $55.7M.
- Aviva fully exited Tiffany & Co. in Q1 2021, selling an estimated $7.08M.
- Aviva's ten largest holdings make up 23% of its $20.5B portfolio in Q1 2021.
- Aviva opened 89 new positions and closed 62 in Q1 2021.
- Aviva's portfolio value rose 6.5% quarter-over-quarter to $20.5B.
Based on Aviva's 13F filing for Q1 2021, filed 13 May 2021.